Richard S. Finn, MD, offers opinion on the role of frontline atezolizumab + bevacizumab in HCC

Riccardo Lencioni, MD, discusses EMERALD-1 results, which he says have “opened a new horizon” in liver cancer and point to a paradigm shift soon.

Sustained clearance of circulating tumor DNA and changes at 6 months with adjuvant therapy are tied to improved disease-free survival in CRC, new data show.

Adjuvant intensity-modulated radiation therapy may prolong RFS in patients with HCC and narrow margins after curative hepatic resection, according to new data.

New data show that first-line nivolumab plus ipilimumab outperforms chemotherapy-based treatment in microsatellite instability-high/mismatch repair-deficient mCRC.

Results of the NETTER-2 trial provide “a new, safe treatment option in a field with no established standard of care,” a study author said.

Results of the EMERALD-1 study show prolonged PFS and open a “new horizon” for patients with unresectable, TACE-eligible HCC, a study author said.

Anticipated presentations at ASCO GI 2024 include insights into early-onset cancer, the use of AI to process biomarker data, and ways to speed up FDA approvals.

After a decade of limited gains in metastatic pancreatic cancer, results of the NAPOLI-3 trial will change care. Zev Wainberg, MD, explains the results.

Quality of life metrics favor tislelizumab over sorafenib with noninferior efficacy in patients with advanced hepatocellular carcinoma, new data show.

For patients with metastatic colorectal cancer, delaying chemotherapy to wait for RAS testing is not necessary, new data show.

Organ preserving treatment for rectal cancer is feasible. “[T]hose who needed surgery can be salvaged without compromising the chance of cure,” an author said.

Addition of bevacizumab to the trifluridine/tipiracil combination in patients with heavily pretreated CRC improved progression-free and overall survival.